Pfizer Inc. is buying Baxter International Inc.'s marketed vaccines portfolio for $635 million.

The portfolio includes the NeisVac-C meningitis vaccine and the tick-born encephalitis vaccine FSME-Immun/TicoVac. Pfizer is also picking up a portion of Baxter's manufacturing facility in Orth, Austria. Pfizer says the deal adds depth and scale to its vaccine portfolio. 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.